Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

ENLV

Enlivex Therapeutics (ENLV)

Enlivex Therapeutics Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ENLV
DateTimeSourceHeadlineSymbolCompany
29/04/202422:00GlobeNewswire Inc.Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent EventsNASDAQ:ENLVEnlivex Therapeutics Ltd
22/04/202422:00GlobeNewswire Inc.Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee OsteoarthritisNASDAQ:ENLVEnlivex Therapeutics Ltd
17/04/202406:55AllPennyStocks.comYet Another Biotech Stock Has Found Success During Tuesday's SessionNASDAQ:ENLVEnlivex Therapeutics Ltd
16/04/202421:50GlobeNewswire Inc.Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee OsteoarthritisNASDAQ:ENLVEnlivex Therapeutics Ltd
12/04/202404:58GlobeNewswire Inc.Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with SepsisNASDAQ:ENLVEnlivex Therapeutics Ltd
11/04/202422:05GlobeNewswire Inc.Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With SepsisNASDAQ:ENLVEnlivex Therapeutics Ltd
08/02/202400:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
08/02/202400:00GlobeNewswire Inc.Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing MethodNASDAQ:ENLVEnlivex Therapeutics Ltd
23/01/202400:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
18/01/202400:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
18/01/202400:00GlobeNewswire Inc.Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee OsteoarthritisNASDAQ:ENLVEnlivex Therapeutics Ltd
21/12/202300:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
10/11/202308:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
08/11/202308:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
03/11/202307:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
27/10/202307:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
18/09/202322:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
14/09/202306:42Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
11/09/202322:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
02/09/202306:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
02/08/202322:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
31/07/202322:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
26/06/202322:03Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ENLVEnlivex Therapeutics Ltd
31/05/202322:10Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ENLVEnlivex Therapeutics Ltd
19/04/202322:03Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ENLVEnlivex Therapeutics Ltd
17/04/202322:04Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ENLVEnlivex Therapeutics Ltd
10/04/202322:01Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:ENLVEnlivex Therapeutics Ltd
04/04/202322:06Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ENLVEnlivex Therapeutics Ltd
03/04/202322:05Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ENLVEnlivex Therapeutics Ltd
01/04/202307:36Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ENLVEnlivex Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:ENLV